RxDoctor Payments Data

Anita Mysliwiec, MD

Internal Medicine · Chicago, ILNPI 1205921319

Payments from drug & device makers

$3,401in general payments, 2019–2025

Across 104 payments — averaging $32.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Pfizer$293
  • Johnson & Johnson$279
  • AbbVie$199
  • Otsuka America Pharmaceutical, Inc.$151
  • Amarin Pharma, Inc.$142
  • plus $855 from 16 others

What the payments were for

  • Food & beverage$3,401100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,401 in reported general payments places this provider in the 85th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$41,789
Medicare patients
92
Services billed
349

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin41$42,093
TrulicityDulaglutide21$22,885
EliquisApixaban27$21,158
OzempicSemaglutide14$13,611
RybelsusSemaglutide13$12,763
Tresiba Flextouch U-100Insulin Degludec16$11,338
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$9,450
Spiriva RespimatTiotropium Bromide12$6,053
Ventolin HfaAlbuterol Sulfate23$1,486
Albuterol Sulfate HfaAlbuterol Sulfate23$1,185
Lisinopril125$1,117
Comfort Ez Pen NeedlePen Needle, Diabetic12$1,024
Omeprazole62$1,018
Levothyroxine Sodium81$855
Nano 2nd Gen Pen NeedlePen Needle, Diabetic12$717

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Spiriva Respimat$16$48,14653 claims
Novo NordiskOzempic, Rybelsus$1,482$26,37327 claims
Lilly USA, LLCTrulicity$138$22,88521 claims
PfizerEliquis$293$21,15827 claims
GSKTrelegy Ellipta$101$9,45014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →